Malignant pleural mesothelioma is a unusual and fast moving tumor for which no effective therapy is around in spite of the breakthrough of quite a few likely molecular and genetic targets. The late stage of Malignant pleural mesothelioma diagnosis and the long latency that between exposures and diagnosis have made it difficult to completely study the role of risk factors and the resulting molecular effects.
A lot of medical centers are now seeing an increasing amount of patients with mesothelioma. Because of this, pathologists studying the case are given a number of problems, which can be broken up into those discovered in distinguishing between mesothelioma and worriless changes and those discovered in differentiating cancer of the mesothelium from different types of e-cadherin and tissue tumors that connect. IHC is a major factor in making the diagnosis, nevertheless it should be interpreted with regards to the clinical setting and radiological characteristics, and with a knowledge of the extensive morphological differentiations that exist in cancer of the mesothelium.
Cancer of the mesothelium is a cancer affecting the serosal cavities, an anatomic location that is frequently affected by metastasis, mostly from primary carcinomas of the ovary, lung and breast. Progression in immunohistochemistry have caused an improved diagnostic sensitivity and mesothelioma in regards to histological and cytological material. Lately, the researchers used a high level of throughput technology to the recognition of new signs that may aid in being able to tell the difference between mesothelioma from ovarian and peritoneal serous carcinoma, closely related histogenesis found in tumors and antigenic profile. Together with the improved tools available for serosal cancer diagnosis, knowledge regarding the biology of cancer of the mesothelium has accumulate recently.
